Archive for the ‘LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management’ Category

The Nobel Prize in Chemistry 2020: Emmanuelle Charpentier & Jennifer A. Doudna

Reporters: Stephen J. Williams, Ph.D. and Aviva Lev-Ari, PhD, RN


Announcement of the Nobel Prize in Chemistry 2020

Live webcast from the press conference where the Royal Swedish Academy of Sciences will announce the Nobel Prize in Chemistry 2020.



The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2020 to

Emmanuelle Charpentier
Max Planck Unit for the Science of Pathogens, Berlin, Germany

Jennifer A. Doudna
University of California, Berkeley, USA

“for the development of a method for genome editing”

Genetic scissors: a tool for rewriting the code of life

Emmanuelle Charpentier and Jennifer A. Doudna have discovered one of gene technology’s sharpest tools: the CRISPR/Cas9 genetic scissors. Using these, researchers can change the DNA of animals, plants and microorganisms with extremely high precision. This technology has had a revolutionary impact on the life sciences, is contributing to new cancer therapies and may make the dream of curing inherited diseases come true.

Researchers need to modify genes in cells if they are to find out about life’s inner workings. This used to be time-consuming, difficult and sometimes impossible work. Using the CRISPR/Cas9 genetic scissors, it is now possible to change the code of life over the course of a few weeks.

“There is enormous power in this genetic tool, which affects us all. It has not only revolutionised basic science, but also resulted in innovative crops and will lead to ground-breaking new medical treatments,” says Claes Gustafsson, chair of the Nobel Committee for Chemistry.

As so often in science, the discovery of these genetic scissors was unexpected. During Emmanuelle Charpentier’s studies of Streptococcus pyogenes, one of the bacteria that cause the most harm to humanity, she discovered a previously unknown molecule, tracrRNA. Her work showed that tracrRNA is part of bacteria’s ancient immune system, CRISPR/Cas, that disarms viruses by cleaving their DNA.

Charpentier published her discovery in 2011. The same year, she initiated a collaboration with Jennifer Doudna, an experienced biochemist with vast knowledge of RNA. Together, they succeeded in recreating the bacteria’s genetic scissors in a test tube and simplifying the scissors’ molecular components so they were easier to use.

In an epoch-making experiment, they then reprogrammed the genetic scissors. In their natural form, the scissors recognise DNA from viruses, but Charpentier and Doudna proved that they could be controlled so that they can cut any DNA molecule at a predetermined site. Where the DNA is cut it is then easy to rewrite the code of life.

Since Charpentier and Doudna discovered the CRISPR/Cas9 genetic scissors in 2012 their use has exploded. This tool has contributed to many important discoveries in basic research, and plant researchers have been able to develop crops that withstand mould, pests and drought. In medicine, clinical trials of new cancer therapies are underway, and the dream of being able to cure inherited diseases is about to come true. These genetic scissors have taken the life sciences into a new epoch and, in many ways, are bringing the greatest benefit to humankind.


The illustrations are free to use for non-commercial purposes. Attribute ”© Johan Jarnestad/The Royal Swedish Academy of Sciences”

Illustration: Using the genetic scissors (pdf)
Illustration: Streptococcus’ natural immune system against viruses:CRISPR/Cas9 pdf)
Illustration: CRISPR/Cas9 genetic scissors (pdf)

Read more about this year’s prize

Popular information: Genetic scissors: a tool for rewriting the code of life (pdf)
Scientific Background: A tool for genome editing (pdf)

Emmanuelle Charpentier, born 1968 in Juvisy-sur-Orge, France. Ph.D. 1995 from Institut Pasteur, Paris, France. Director of the Max Planck Unit for the Science of Pathogens, Berlin, Germany.

Jennifer A. Doudna, born 1964 in Washington, D.C, USA. Ph.D. 1989 from Harvard Medical School, Boston, USA. Professor at the University of California, Berkeley, USA and Investigator, Howard Hughes Medical Institute.




Nobel Prize in Chemistry awarded to scientists who discovered CRISPR gene editing tool for ‘rewriting the code of life’

(CNN)The Nobel Prize in Chemistry has been awarded to Emmanuelle Charpentier and Jennifer A. Doudna for the development of a method for genome editing.

They discovered one of gene technology’s sharpest tools: the CRISPR/Cas9 genetic scissors. Using these, researchers can change the DNA of animals, plants and micro-organisms with extremely high precision.
Before announcing the winners on Wednesday, Göran K. Hansson, secretary-general for the Royal Swedish Academy of Sciences, said that this year’s prize was about “rewriting the code of life.”
The American biochemist Jennifer A. Doudna (left) and French microbiologist Emmanuelle Charpentier, pictured together in 2016.
The CRISPR/Cas9 gene editing tools have revolutionized the molecular life sciences, brought new opportunities for plant breeding, are contributing to innovative cancer therapies and may make the dream of curing inherited diseases come true, according to a press release from the Nobel committee.
There have also been some ethical concerns around the CRISPR technology, however.
Charpentier, a French microbiologist, and Doudna, an American biochemist, are the first women to jointly win the Nobel Prize in Chemistry, and the sixth and seventh women to win the chemistry prize.
close dialog


Jennifer Doudna wins 2020 Nobel Prize in chemistry


First Day in a Nobel Life: Jennifer Doudna

Oct 7, 2020
Scenes from day that UC Berkeley Professor Jennifer Doudna won the Nobel Prize For the full story, visit: https://news.berkeley.edu/2020/10/07/… University of California, Berkeley, biochemist Jennifer Doudna today won the 2020 Nobel Prize in Chemistry, sharing it with colleague Emmanuelle Charpentier for the co-development of CRISPR-Cas9, a genome editing breakthrough that has revolutionized biomedicine. CRISPR-Cas9 allows scientists to rewrite DNA — the code of life — in any organism, including human cells, with unprecedented efficiency and precision. The groundbreaking power and versatility of CRISPR-Cas9 has opened up new and wide-ranging possibilities across biology, agriculture and medicine, including the treatment of thousands of intractable diseases. Doudna and Charpentier, director of the Max Planck Institute for Infection Biology, will share the 10 million Swedish krona (more than $1 million) prize. “This great honor recognizes the history of CRISPR and the collaborative story of harnessing it into a profoundly powerful engineering technology that gives new hope and possibility to our society,” said Doudna. “What started as a curiosity‐driven, fundamental discovery project has now become the breakthrough strategy used by countless researchers working to help improve the human condition. I encourage continued support of fundamental science as well as public discourse about the ethical uses and responsible regulation of CRISPR technology.” Video by Clare Major & Roxanne Makasdjian


Jennifer Doudna wins 2020 Nobel Prize in chemistry


Jennifer Doudna in the PBS Movie CRISPR

Our critically-acclaimed documentary HUMAN NATURE is now streaming on NETFLIX. #HumanNatureFilm. Find out more about the film on our website.


Other Articles on the Nobel Prize in this Open Access Journal Include:

2020 Nobel Prize for Physiology and Medicine for Hepatitis C Discovery goes to British scientist Michael Houghton and US researchers Harvey Alter and Charles Rice

CONTAGIOUS – About Viruses, Pandemics and Nobel Prizes at the Nobel Prize Museum, Stockholm, Sweden 

AACR Congratulates Dr. William G. Kaelin Jr., Sir Peter J. Ratcliffe, and Dr. Gregg L. Semenza on 2019 Nobel Prize in Physiology or Medicine

2018 Nobel Prize in Physiology or Medicine for contributions to Cancer Immunotherapy to James P. Allison, Ph.D., of the University of Texas, M.D. Anderson Cancer Center, Houston, Texas. Dr. Allison shares the prize with Tasuku Honjo, M.D., Ph.D., of Kyoto University Institute, Japan

2017 Nobel prize in chemistry given to Jacques Dubochet, Joachim Frank, and Richard Henderson  for developing cryo-electron microscopy

2016 Nobel Prize in Chemistry awarded for development of molecular machines, the world’s smallest mechanical devices, the winners: Jean-Pierre Sauvage, J. Fraser Stoddart and Bernard L. Feringa

Correspondence on Leadership in Genomics and other Gene Curations: Dr. Williams with Dr. Lev-Ari

Programming life: An interview with Jennifer Doudna by Michael Chui, a partner of the McKinsey Global Institute

Read Full Post »

The 40th Anniversary of SRI ORGANON TOASTMASTERS virtual celebration on Tuesday, August 18, 11:45 a.m.-1:00 p.m

Past Member of SRI Organon Toastmasters, 5/1985 – 9/1988: Aviva Lev-Ari, PhD, RN


I was a Competent Toastmasters working on the Distinguished Toastmasters rank.

Today, 8/7/2020 was invited to attend the SRI Organon Toastmasters 40th Anniversary. 

The picture on my Student ID Card at University of California, Berkeley, 9/1978 – 12/1983


From: NAOMI LEVENSON <na8mi@comcast.net>

Date: Friday, August 7, 2020 at 3:38 PM

Subject: SRI Organon Anniversary

SRI Organon Toastmasters turned 40 in February!

We invite you to join the virtual celebration on Tuesday, August 18, 11:45 a.m.-1:00 p.m.



More information is on the attached flyer.

Plan to come to the meeting early and stay afterwards. There will be time to reminisce and catch up.

Do you have any memories you might want to share. You can add your thoughts, anecdotes and comments on   https://tinyurl.com/yxl4nuu4.

Bring your own beverage for the TOAST!

Please plan to attend.

Naomi Levenson


40th Anniversary Flyer (1)

Read Full Post »

LPBI Group’s Founder – A Profile for a Wikipedia Entry

Curator: Zach Day, with editorial comments by Prof. Marcus W. Feldman, Dr. Joel T. Shertok, PhD and Gail S. Thornton, PhD(c), MA


Aviva Lev-Ari, Ph.D., R.N.



Aviva Lev-Ari, Ph.D., R.N., is the founder of Leaders in Pharmaceutical Business Intelligence Group (LPBI Group), a Newton, Massachusetts, start-up company launched in 2012 in the domain of Pharmaceutical Media.

The LPBI Group incorporates into three interrelated domains:

  • an open-access online scientific journal,
  • a series of 16 BioMed e-books covering five specialties of Medicine and Life Sciences (Cardiovascular, Genomic Medicine, Cancer, Immunology and Precision Medicine) and
  • real-time press coverage of BioMed scientific and medical conferences.

Year over year, LPBI Group continues to increase its readership of medically valuable content, which includes more than 5,800 scientific articles with over 1.8 million views in its online scientific journal. The LPBI Group goal is to make scientific content universally accessible to the pharmaceutical media and electronic scientific publishing communities.

https://pharmaceuticalintelligence.com/ at @pharma_BI and @AVIVA1950. Additionally, the 16 BioMed e-books can be accessed on the website: https://pharmaceuticalintelligence.com/biomed-e-books/ and on https://lnkd.in/ekWGNqA

Please visit the LPBI Group Wikipedia page to learn more about our company. [ZACH: CAN YOU PUT A LINK TO THE LPBI GROUP Wikipedia Page here?] 

Ongoing Commitment to Life Sciences

The LPBI Group team curates life sciences and medical literature producing clinical interpretations of scientific findings and publishing the results as articles in LPBI Group’s open-access online scientific Journal http://pharmaceuticalintelligence.com.

Dr. Lev-Ari serves as Editor-in-Chief of the Journal and of the series of 16 BioMed e-books. The e-Books cover five cardinal Medical specialties https://lnkd.in/ekWGNqA. The books serve physicians in the community, allied healthcare professionals, medical students and an extensive global community of e-readers in life sciences and biomedicine. The books are also included in the medical curricula of several prominent medical schools in the United States.

The LPBI Group has competencies in real-time coverage of Medical and Biotech global conferences, using methodology developed by Dr. Lev-Ari. This method allows for the generation of e-Proceedings with a single click. Dr. Lev-Ari developed a series of templates used during the Conferences to generate Tweets representing quotes by speakers and their affiliations. To date Dr. Lev-Ari has generated 60 e-Proceedings and 36 Tweet Collections. Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics


Early Life and Education

Dr. Aviva Lev-Ari was born in Bucharest, Romania, to a Jewish family with a 400-year history in Europe. Along with her father and older sister, Pnina Abir-Am, Ph.D. [Brandeis University], the family moved to Israel in December 1958. [Her mother succumbed to breast cancer in September 1956 when Aviva was 6 years old].  As a young girl in a 10-year-old State of Israel, the new reality was significantly different than that of her European early years. She loved oranges and bananas both of which were rare in Eastern Europe in the 50s. She bonded with the nature and the geography of Israel, the wild flowers of the hilly slopes of Mount Carmel and the wide panoramic view of the Western bound of the Valley of Jezreel from the window of her bedroom shared with her sister. Dr. Lev-Ari graduated with honors from the prestigious private institution, Huggim High School on Mount Carmel, in Haifa in 1968. This gymnasium was established in 1932 by German Jewish emigres, who were former German University Professors, forced to leave their Academic positions by the Nazis.

These high school years made a long lasting impression on Aviva, a studious, achievement–oriented, hardworking student who was motivated to excel in her studies.

Following her IDF military service, she studied at the Hebrew University (HUJI) in Jerusalem for six years, where she earned her B.A. and M.A. degrees (Cum Laude) in Urban Planning and Economic Geography in 1976. At HUJI she became a very scholarly-inclined student, motivated by the outstanding faculty members, i.e., Prof. S. Reichman and Prof. Louis Guttman.

Her Masters thesis applied Facet Theory, SSA, MSA & POSAC, the novel non-parametric paradigm in Statistics developed by Prof. Louis Guttman in 1946 and during the 60s and the 70s, while using the latest version of the computer programs that were included for the 1st year in SPSS in 1976. The thesis was filed with the Graduate Division in July 1976, conferring and confirming the highest GPA recorded at the registrar of the Faculty of Social Sciences at HUJI to-date (95/100).

She then worked at the Technion, which was known to hire chiefly its own graduates, in Applied Research as the first HUJI graduate to be hired. During 1977-1978 at the Technion, she applied Facet Theory in Urban Planning. She came to the United States to pursue her doctoral studies in September 1978. Her postgraduate studies were at the University of California – Berkeley, where she earned her doctorate in 1983 in Industrial Organization Economics and Location Theory under Prof. Allan Pred, a famous AAAG Fellow +40 years of the 20th century on the Faculty at Berkeley, the #2 Department of Geography in the country. The Berkeley academic environment was most conducive for interdisciplinary research and for expression of the highest level of creativity; both were Prof. Allan Pred’s contributions as mentor and as advisor to Aviva. The intellectual stimulation culminated in her Ph.D. thesis, and other milestones beyond the years at Berkeley. Prof. Pred presented a draft of her dissertation at MIT in October 1983. Recollections of Years at UC, Berkeley, Part 1 and Part 2:

  • Recollections: Part 1– My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Prof. Allan Pred, other professors and other peers


  • Recollections: Part 2– “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83



Additionally, Dr. Lev-Ari was Prof. Louis Guttman’s student in 1975-76. She was known for applying his methods in the top-tier consulting industry in the United States using the software licensed via Yissum (Technology Transfer Office of HUJI) at SRI International for Fortune 50 companies e.g., GM, Alcan, Rhone Poulenc. At the University of California – Berkeley, she taught upper division courses in Quantitative Methods using SSA, MSA & POSAC in 1979, 1980, 1981. In 1990-91, she was the developer of the models that made a cardinal organizational change from managerial to brokerage agencies by a top financial & insurance firm based in Boston, Massachusetts, where she spent the fall and winter of 1990/91 on the 52nd floor of one of the two tallest skyscrapers in Boston.

While in California, she also studied Organizational Behavior under James G. March and Harold J. Leavitt at Stanford University Graduate School of Business, in an Exchange Program between Berkeley and Stanford in 1980-81.

Autobiographical Annotations: Tribute to My Professors


Dr. Lev-Ari worked in the domains of her expertise for 25 years, at several of the most esteemed institutions in the United States, among them, SRI International – Menlo Park, California; MITRE – Bedford, Massachusetts; PSC – Cambridge, Massachusetts (HQS: Dallas, TX); and McGraw Hill – Monterey, California (HQS: NY, NY).

Dr. Lev-Ari reinvented her career toward a new direction in Health Care, by being admitted into the Bouve College of Health Sciences in 2005, and earning a nursing degree at Northeastern University (Nurse Practitioner Direct Entry track – 800 candidates for 26 places.) For comparison, at the Ph.D. Program Admission, there were 240 candidates for 12 places and only 8 earned the degree five years later.

At Northeastern University she researched cardiovascular pharmacotherapy with her professor of Pharmacology for four independent research courses during 2006-2007. Pharmacology was the domain she liked the most at Bouve College. She developed the concept of a combination drug therapy (three agents) for prevention of macro cardiovascular events. She already knew then, that she would return to pharmaceutical study some day.


Reflections on a Four-phase Career

Dr. Lev-Ari’s career, as presented in Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018, has the following phases:

  • Phase 1: Research, 1973 – 1983
  • Phase 2: Corporate Applied Research in the US, 1985 – 2005
  • Phase 3: Career Reinvention in Health Care, 2005 – 2012
  • Phase 4: Electronic Scientific Publishing, 4/2012 to present


This article was written in March 2018. It was prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter, Hebrew University’s HUJI Alumni Spotlight Section.

Aviva Lev-Ari’s profile was up on 5/3/2018 on AFHU website under the Alumni Spotlight at https://www.afhu.org/


Early Career

Dr. Lev-Ari started her career conducting research from 1973 -1983.  She then transitioned into Corporate Applied Research in the United States between 1985-2005.

Second Career

Dr. Lev-Ari reinvented her career in the Health Care arena, and earned her R.N. degree. She worked in Clinical Nursing Management, 2008–2012, in post-acute settings and was Supervisor of a Long-Term Acute Care Hospital (LTACH) in Waltham, Massachusetts.

Recent Career

Dr. Lev-Ari’s most recent transition has been into Electronic Scientific Publishing, from April 2012 to the Present. Currently she is the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group. She is the developer of several curation methodologies for scientific content, and developed a unique methodology for the creation of an electronic Table of Contents (eTOCs). She was initiated into the development of workflow procedures involved in the systematic population of all eTOCs by Expert Editors, that culled articles from the journals’ research categories to create a one of a kind eTOCs for each volume [except for Cancer Volume 1].

In 2012, Dr. Lev-Ari launched, and currently leads the Journal, PharmaceuticalIntelligence.com. She is the Editor in Chief of the Journal and of the BioMed e-Series. The transformative work done at LPBI Group allows cutting-edge biomedical research innovation to be widely disseminated and accessible to the research and the non-research communities. Her method of curation represents a mode of scientific communication including synthesis, analysis, and interpretation.

Experts, authors, and writers add their knowledge and expertise in re-thinking and conceptualizing subjects selected in their domain of expertise, to form new curations or updating existing ones. The books are transformative in their capacity to accelerate diffusion of scientific innovations. To date 115,000 pages have been downloaded form the 16 Volumes.

The curation is done by experts with a perspective within each field, allowing for the creation of scientific content that combines conceptual evolution within the scientific breakthroughs analyzed with their anticipated future implications.

Dr. Lev-Ari’s work is innovative and creative. She has perfected the art of scientific curation for medical evaluation of cutting-edge literature. It is available through LPBI Group’s open access Journal. Dr. Lev-Ari has tutored numerous students and young adults in her career. LPBi is enjoying an excellent reputation within the field, for the valuable information it provides. Dr. Stephen Williams, a Professor of Pharmacology at the Sbarro Health Research Organization at Temple University said of Dr. Lev-Ari,

“I have never met anyone so driven as Dr. Lev-Ari. She had a great vision and knows how to put that vision into practice. She has an impressive amount and quality of people she has direct contact with.” Regarding Dr. Lev-Ari’s accomplishments and personal character, he noted: “She has more energy than some 20 and 30-somethings. She does not stop until she sees her vision realized.”

Personal Life

Dr. Lev-Ari married in 1971 a newly minted graduate of the Technion and Officer in the Signal Corps of IDF. Hanoch Lev-Ari, Ph.D., Fellow IEEE, has been a Professor of EE at Northeastern University since 1990. He is a graduate of Stanford University, Ph.D. ’84 in EE, and the Technion, BSEE ’71 & MSEE ’76. They lived in Palo Alto, California from 1978-1990 and in Newton Center, Massachusetts since September 1990. They have one married son, Edan, a 2007 Cornell University graduate working at Natick Lab, Natick, MA

Dr. Lev-Ari enjoys swimming, classical music, Jazz, non-fiction literature, fashion design, fashion photography, orchids and peonies.




Dr. Lev-Ari’s expertise is in Cardiovascular Diseases



  1. Cardiovascular Diseases, Volume One: Perspectives on Nitric Oxide in Disease Mechanisms. On comsince 6/21/2013 https://lnkd.in/8DANfq
  2. Cardiovascular Diseases, Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation. On comsince 11/30/2015 https://lnkd.in/ekbuNZ3
  3. Cardiovascular Diseases, Volume Three: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics. On comsince 11/29/2015 https://lnkd.in/ecp5mrA
  4. Cardiovascular Diseases, Volume Four: Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases. On comsince 12/26/2015 https://lnkd.in/dwqM3K3
  5. Cardiovascular Diseases, Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases. On comsince 12/23/2018 https://lnkd.in/e3r87cQ
  6. Cardiovascular Diseases, Volume Six: Interventional Cardiology for Disease Diagnosis and Cardiac Surgery for Condition Treatment. On comsince 12/24/2018 https://lnkd.in/e_CTb4R





















Nomination for 2018 Yidan Prize, recognition in the field of medical education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN


  • Dr. Lev-Ari was nominated for the 2020 Campanile Excellence in Achievement Award, December 5, 2019.
  • Dr. Lev-Ari was nominated for 2019 Berkeley Alumna of the Year Achievement Award, December 7, 2018,








Read Full Post »

WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com

Curators: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD, Aviva Lev-Ari, PhD, RN


Article Name
Live Link
All Time
Categories of Research 


Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?

17,140Biological NetworksCANCER BIOLOGY & Innovations in Cancer TherapyCell BiologyDisease BiologyGenome BiologyImaging-based Cancer Patient ManagementInternational Global Work in PharmaceuticalLiver & Digestive Diseases ResearchMetabolomicsMolecular Genetics & PharmaceuticalNutritionPharmaceutical Industry Competitive IntelligencePharmaceutical R&D InvestmentPopulation Health ManagementProteomicsStem Cells for Regenerative MedicineTechnology Transfer: Biotech and Pharmaceutical | Tagged Adenosine triphosphateATPGlycolysisHypoxia-inducible factorsKrebLactate dehydrogenaseMammalian target of rapamycinMitochondrionWarburg Effect


Recent comprehensive review on the role of ultrasound in breast cancer management

14,553Biomarkers & Medical DiagnosticsHealth Economics and Outcomes ResearchHealthcare costs and reimbursementImaging-based Cancer Patient ManagementMedical Device Therapies for Altzheimer’s DiseaseMedical Devices R&D InvestmentMedical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound | Tagged breast biopsiesbreast cancerbreast cancer managementbreast cancer screeningbreast cystbreast lesionsbreast ultrasoundmammographyMRIPersonalized medicinePETsupport breast cancertomosynthesisyale university schoolyale university school of medicine 


Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)

13,893Coagulation Therapy and Internal BleedingElectrophysiologyFDA Regulatory AffairsOrigins of Cardiovascular DiseasePharmacotherapy of Cardiovascular Disease | Tagged Academic Medical CenterAmsterdamAnticoagulantApixabanDabigatranDirect thrombin inhibitorDirect Xa inhibitorFood and Drug AdministrationNew England Journal of MedicineNon-steroidal anti-inflammatory drugNortheastern UniversityPRADAXAProthrombin timeRivaroxabanVTEWarfarin 


Paclitaxel vs Abraxane (albumin-bound paclitaxel)cent comprehensive review on the role of ultrasound in breast cancer management

13,878BioSimilarsCANCER BIOLOGY & Innovations in Cancer TherapyDisease Biology, Small Molecules in Development of Therapeutic DrugsNanotechnology for Drug DeliveryPharmaceutical AnalyticsPharmaceutical R&D InvestmentRegulated Clinical Trials: Design, Methods, Components and IRB related issues | Tagged Abraxanealbumin-bound paclitaxelbreast cancerclinical studiesFREE paclitaxellinear PKnon-linear PKPaclitaxelPharmacokineticsPKside effectsTaxol 


Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications

8,367Coagulation Therapy and Internal BleedingFrontiers in Cardiology and Cardiovascular DisordersOrigins of Cardiovascular DiseasePharmacotherapy of Cardiovascular Disease, tagged Dabigatranrivaroxaban and apixaban for stroke prevention in atrial fibrillation 


Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care

8,068Medical Devices R&D InvestmentNitric Oxide in Health and DiseaseTechnology Transfer: Biotech and Pharmaceutical | Tagged ARDSAviva Lev-AriInhaled Nitric Oxidenitric oxideprostacyclinPulmonary hypertensionRespiratory failure 

Our Team

6,553LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management 
Mesothelin: An early detection biomarker for cancer (By Jack Andraka)
6,545Advanced Drug Manufacturing TechnologyBio Instrumentation in Experimental Life Sciences ResearchBiological Networks, Gene Regulation and EvolutionBiomarkers & Medical DiagnosticsBioSimilarsCANCER BIOLOGY & Innovations in Cancer TherapyCancer Prevention: Research & ProgramsCell Biology, Signaling & Cell CircuitsDisease Biology, Small Molecules in Development of Therapeutic DrugsHealth Economics and Outcomes ResearchMedical Devices R&D InvestmentNanotechnology for Drug DeliveryPharmaceutical R&D InvestmentPopulation Health Management, Genetics & PharmaceuticalRegulated Clinical Trials: Design, Methods, Components and IRB related issuesTechnology Transfer: Biotech and Pharmaceutical | Tagged Blood testcarbon nanotubesearly detectionMesothelinPancreatic cancer 


Biochemistry of the Coagulation Cascade and Platelet Aggregation: Nitric Oxide: Platelets, Circulatory Disorders, and Coagulation Effects

5,235Aortic Valve: TAVR, TAVI vs Open Heart SurgeryBiomarkers & Medical DiagnosticsCell Biology, Signaling & Cell CircuitsChemical Biology and its relations to Metabolic DiseaseCoagulation Therapy and Internal BleedingDisease Biology, Small Molecules in Development of Therapeutic DrugsMetabolomicsMitral Valve: Repair and ReplacementNitric Oxide in Health and DiseasePersonalized and Precision Medicine & Genomic ResearchPharmaceutical Industry Competitive IntelligencePharmacotherapy of Cardiovascular DiseasePopulation Health Management, Nutrition and PhytochemistryProteomics | Tagged anti-inflammatoryanti-TNFAnticoagulantAntithrombinblood flow resistancecell junctionscellular adhesionCoumadinEndothelial cellsFactor IX and IXaFactor VII and VIIaFactor VIII and Factor VIIIaFactor X and XafibrinogenfibrinolysisheparinHypoxia-inducible factorsNon-steroidal anti-inflammatory drugPartial thromboplastin timePhysiologyplasminplatelet aggregationplateletsprothrombinsoluble fibrinsubendothelial matrixThrombinthrombomodulinThrombustissue factorTNF-aVon Willebrand factorWH Seegers 

Interaction of enzymes and hormones

5,173Cell Biology, Signaling & Cell CircuitsChemical Biology and its relations to Metabolic DiseaseMetabolomicsPopulation Health Management, Genetics & PharmaceuticalPopulation Health Management, Nutrition and PhytochemistryReproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics | Tagged active compoundsenzymehormoneinteractionMetabolismTherapy 


Akt inhibition for cancer treatment, where do we stand today?

4,865CANCER BIOLOGY & Innovations in Cancer TherapyCell Biology, Signaling & Cell Circuits | Tagged Cancer researchcancer therapyCell BiologymTORNF-κBPI3K/AKT pathwayPTENSignal transduction 



The History and Creators of Total Parenteral Nutrition




Disease BiologyGastroenterologyUncategorized | Tagged Amino acidsenteral nutritionNutritionTPN



Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?

Article #1: WordCloud by DM


Recent comprehensive review on the role of ultrasound in breast cancer management

Article #2: WordCloud by NT


Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)

Article #3: WordCloud by ZD


Paclitaxel vs Abraxane (albumin-bound paclitaxel)cent comprehensive review on the role of ultrasound in breast cancer management

Article #4: WordCloud by DM


Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications

Article #5: WordCloud by ZD


Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care

Article #6: WordCloud by NT


Our Team

Article #7: WordCloud by DM

Read Full Post »

LPBI’s Accomplishments 1Q 2020 & 2Q 2020

Reporter: Aviva Lev-Ari, PhD, RN


1. LPBI’s External Scientific Relations

  • They all are presenting at LPBI’s Monthly Zoom Meetings on 2nd Tuesday of the month, 11AM EST – 2PM EST
  • Among them: SY, AG, YB, RN,
  • Each is serving as a Reference to LPBI for the Exit purpose
  • Each is serving as a Reference to LPBI’s Founder for the Exit purpose

2. LPBI’s External Business relations

  • Among them: Dr. Mak, AB, GG, AA
  • Each is to take a ROLE in the Exit
  • AB & GG will work together

HAPPY to report a WIN: SY will be represented by AB in two top Big Pharma scenes

3.  LPBI’s Internal Reorganization to be announced June 23, 2020

  • Twelve Economic Segments for LPBI Group’s IP – Prospects for Transfer of Ownership

  1.       Holding Company and Investment Banker
  2.       Information Technology Companies – Health Care
  3.       Scientific Publishers
  4.       Big Pharma
  5.       Internet Health Care Media & Digital Health
  6.       Online Education
  7.       Health Insurance Companies & HMOs
  8.       Medical and Pharma Associations
  9.       Medical Education
  10.       Information Syndicators
  11.       Global Biotech & Pharmaceutical Conference Organizer
  12.       CRO & CRA
  • Generic Business side are changing roles to serve Industrial VERTICALS
  • In the Industrial VERTICALS Plan every FIT Member on the Business side and Business-Science side is proposed a Vertical to pursue
  • ACTION POINT: Each Industrial VERTICAL Lead will schedule three meetings between July 10, 2020 and December 20, 2020 for presentation of LPBI by SJW, JTS, ALA to key enterprises in their VERTICAL
  • Proposed Industrial VERTICALS for Business-side to lead are as follows:


  • IT sector Cloud-based Amazon Web Services (AWS), Alphabet – Verily, Apple-Health, IBM Watson
  • Server-Cloud: Intel-Health, Microsoft-Health, Oracle-Health, DELL, SAAP


  • Big Pharma: J&J, Roche, Novartis, Pfizer, Bayer, Merck, GSK, Sanofi, Abbvie, Abbott, Eli Lilly, Amgen, BMS, Gilead, AstraZeneca, TEVA, BI, NovoNordisk, Allergen, Takeda+Shire, Celgene, Biogen
  • CROs
  • Internet Health Care Media (MedScape, UptoDate) [work with GST]


  • To be announced on 6/23/2020, incoming Board Member
  • Industrial VERTICAL in the Financial Sector:
  1. Holding Companies: Internet Brands of KKR, Temasek, NMC, Generex
  2. Health Insurance Companies & HMOs

GST: Media Content-driven:

  • Information Syndicators
  1. Reuters Clarivate [work with JSZ & JTS] &
  2. Springer [work with SJW]
  • Medical and Pharma Associations


  • To be announced on 6/23/2020, incoming Chief Scientific Officer
  • Education Sector
    • Medical Schools


  • Education Sector
    • Online Education [work with IR]


  • Global Biotech & Pharmaceutical Conference Organizers
  • Israel & Europe

THESE announcements will all be included in the new Organization Chart presented in

  • Zoom Meeting on June 23, 2002 at 2PM EST – 5PM EST
  • I am with the Summer Interns 6/23, 11AM EST – 2PM EST
  • Zoom Invitations will go out on 6/22/2020

3. New significant members joined LPBI Team as ACTIVE FIT Members since January 2020:

  • JTS – Industrial VERTICALS: Financial Sector. Effective 6/23/2020 Board Member
  • JSZ – Industrial VERTICALS: Big Pharma & CRO
  • OM – Artificial Intelligence for Text Analysis, 2020 Summer Internship Lead, Industrial VERTICALS: Global Conference Organizers. REGIONS; Israel & Europe
  • DM – Acting CTO

4. THREE or Four Student-Interns for LPBI’s 2020 Summer Internship Program

  • DM – Replied to my AD
  • SS – Sourced by Robin
  • NST – Sourced by Robin
  • ZD – an LPBI Returning Intern from 2019 – Confirmed by e-mail, Updated Resume Upload – PENDING

5. Acting CTO applied for LPBI’s Enterprise Twitter Developer Account.

  • Application approved in two rounds.
  • Daniel uses Teepy & Pyton on CORE Application Development Projects with ALA

6. Data on Twitter shows REACH via 2nd degree at ~18 MM

7. LPBI has two Twitter Handles with combined Followers of +1,000 – @pharma_BI @AVIVA1950

8. LPBI’s Library Slide Deck has 140 slides, each slide has in the footer the initials of slide’s curator. [11 slides are by GST & RAM, 50% by GST].

9. LPBI’s Brochure has 40 Pages – rewritten per Mr. Bahl’s comments. JTS is Owner of that document.

  • Appended comments by JSZ to comments by Mr. Bahl. No use made for betterment of document.

10.  LPBI’s Business Plan serves as venture’s Prospectus. It includes 26 comments by Mr. Bahl, and ALA responses to these comments. This process yielded 22 new pages of content not in existence in version 3/19/2020. Prospectus is 240 pages.

  • Document version 3-19-2020 includes comments by GST, IR, SJW, OM. Computations by JTS, JTS & ALA, ALA and DM & ALA. Tables by OM, ALA & OM, ALA & SJW and charts by JTS.
  • Appended comments by JSZ to comments by Mr. Bahl (85%, “I agree”). No use made for betterment of document.

11. Founder, as Editor-in-Chief, had launched MOST TIMELY AND SWIFTLY on March 14, 2020 the Coronavirus Portal


Eight Pages of LPBI Group’s Coronavirus PORTAL VIEWED by +2,000 e-Readers

  1. Breakthroughs
  2. Development of Medical Counter-measures for 2019-nCoV, CoVid19, Coronavirus
  3. An Epidemiological Approach Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN Lead Curators – e–mail Contacts: sjwilliamspa@comcast.net and avivalev-ari@alum.berkeley.edu
  4. Community Impact Stephen J. Williams, PhD and Irina Robu, PhD Lead Curators – e–mail Contacts: irina.stefania@gmail.com and sjwilliamspa@comcast.net
  5. Economic Impact of The Coronavirus Pandemic Dr. Joel Shertok, PhD Lead Curator – e–mail Contact: jshertok@processindconsultants.com
  6. Voices of Global Citizens: Impact of The Coronavirus Pandemic Gail S. Thornton, M.A. Richard A. Mandahl, MBA and Sudipta Saha, PhD Lead Curators – e–mail Contacts: gailsthornton@yahoo.com and rmandahl@gmail.com and sudiptasaha1977@gmail.com
  7. Diagnosis of Coronavirus Infection by Medical Imaging and Cardiovascular Impacts of Viral Infection Dr. Jason Zielonka, MD, AFACC and Aviva Lev-Ari, PhD, RN Lead Curators e-mail contacts: Jasonz.mit@gmail and avivalev-ari@alum.berkeley.edu
  8. Key Opinion Leaders Followed by LPBI Aviva Lev-Ari, PhD, RN and Dr. Ofer Markman, PhD Lead Curators e-mail contacts; oferm2015@gmail.com and avivalev-ari@alum.berkeley.edu

12. AI Portal was launched for LPBI’s New Direction Pipeline in Text Analysis by Machine Learning, NLP, AI on LPBI’s Three CORPUSES: Journal, e-Books, e-Proceedings & Tweet Collections


13. Knowledge Portals System was launched for Human Resource Management in the iCloud as One Point of Profile View and Performance Review – ALL information on each FIT members to be shared with Prospect Acquirers upon request.


14. 2020 Summer Internship PORTAL launched on 6/16/2020 following the Kick off Meeting introducing the interns.

2020 Summer Internship PORTAL is in use by

  • INTERNS – Each has a Personal Page: Daniel M. Sonam S, Noam S-T 
  • DELIVERABLES by INTERNS to be used for a PROOF OF CONCEPT on three types of Cancer from our Journal Articles
  • INSTRACTORS’ Assignments: Lead, OM
  • PRESENTERS PowerPoints: ALA, SJW, IR, OM


Read Full Post »

Top Articles in PharmaceuticalIntelligence.com by Number of Views > 3,500 Views, Author(s) Names and Article Type [6/2/2020 counting date]: Relations between Article Type and Article Views

Reporter: Aviva Lev-Ari, PhD, RN


Website Statistics on June 2, 2020

All time



5,834 Scientific articles

705 Categories of research 

10,283 Tags

Top Authors for all days ending 2020-06-02 (Summarized)

All Time

Author Views
2012pharmaceutical 445,444
larryhbern 322,959
tildabarliya 64,468
sjwilliamspa 61,198
Dror Nir 35,190
Dr. Sudipta Saha 33,704
Demet Sag, Ph.D., CRA, GCP 17,972
ritusaxena 17,166
Gail S Thornton 13,528
aviralvatsa 9,095
zraviv06 8,939
danutdaagmailcom 5,478
Irina Robu 5,432
zs22 4,366


Number of Views on 2/6/2020 Investigator Initiated Research Article Commissioned by Aviva Lev-Ari, PhD, RN
Larry H. Bernstein, MD, FCAP 17,117
Dr. Pearlman, MD, PhD, FACC, Larry H. Bernstein, MD, FCAP & Aviva Lev-Ari, PhD, RN 4,038
Dr. Pearlman, MD, PhD, FACC & Aviva Lev-Ari, PhD, RN 7,903 13,839
Tilda Barliya 13,709
Aviva Lev-Ari, PhD, RN 8,230 3,895
Ziv Raviv 4,852
Stephen J. Williams, PhD 4,535
Zohi Sternberg 4,365
Dr. D. Nir 14,242
Total 76,660 45,426
% 62.8% 37.2%
Top Posts for all days ending 2020-06-02 (Summarized)      
All Time      
Title Views Author Name Type of Article
Home page / Archives 676,690 Internet Access Tabulation
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? 17,117 Larry H. Bernstein, MD, FCAP Investigator Initiated Research
Recent comprehensive review on the role of ultrasound in breast cancer management 14,242 Dr. D. Nir Commission by Aviva Lev-Ari, PhD, RN
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) 13,839 Dr. Pearlman, MD, PhD, FACC & Aviva Lev-Ari, PhD, RN Commission by Aviva Lev-Ari, PhD, RN
Paclitaxel vs Abraxane (albumin-bound paclitaxel) 13,709 Tilda Barliya, PhD Investigator Initiated Research
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications 8,230 Aviva Lev-Ari, PhD, RN Investigator Initiated Research
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care 7,903 Dr. Pearlman, MD, PhD, FACC & Aviva Lev-Ari, PhD, RN Investigator Initiated Research
Mesothelin: An early detection biomarker for cancer (By Jack Andraka) 6,540 Tilda Barliya, PhD Investigator Initiated Research
Our TEAM 6,505 Internet Access Tabulation
Biochemistry of the Coagulation Cascade and Platelet Aggregation: Nitric Oxide: Platelets, Circulatory Disorders, and Coagulation Effects 5,221 Larry H. Bernstein, MD, FCAP Investigator Initiated Research
Interaction of enzymes and hormones 4,901 Larry H. Bernstein, MD, FCAP Commission by Aviva Lev-Ari, PhD, RN
Akt inhibition for cancer treatment, where do we stand today? 4,852 Ziv Raviv, PhD Investigator Initiated Research
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation 4,535 Stephen J. Williams, PhD Investigator Initiated Research
The History and Creators of Total Parenteral Nutrition 4,511 Larry H. Bernstein, MD, FCAP Commission by Aviva Lev-Ari, PhD, RN
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses 4,365 Zohi Sternberg, PhD Investigator Initiated Research
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules 4,188 Stephen J. Williams, PhD Investigator Initiated Research
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets 4,038 Dr. Pearlman, MD, PhD, FACC, Larry H. Bernstein, MD, FCAP & Aviva Lev-Ari, PhD, RN Commission by Aviva Lev-Ari, PhD, RN
Founder 3,895 Aviva Lev-Ari, PhD, RN Investigator Initiated Research


Read Full Post »

Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Symposium: New Drugs on the Horizon Part 3 12:30-1:25 PM

Reporter: Stephen J. Williams, PhD

New Drugs on the Horizon: Part 3

Andrew J. Phillips, C4 Therapeutics

  • symposium brought by AACR CICR and had about 30 proposals for talks and chose three talks
  • unfortunately the networking event is not possible but hope to see you soon in good health

ABBV-184: A novel survivin specific T cell receptor/CD3 bispecific therapeutic that targets both solid tumor and hematological malignancies

Edward B Reilly
AbbVie Inc. @abbvie

  • T-cell receptors (TCR) can recognize the intracellular targets whereas antibodies only recognize the 25% of potential extracellular targets
  • survivin is expressed in multiple cancers and correlates with poor survival and prognosis
  • CD3 bispecific TCR to survivn (Ab to CD3 on T- cells and TCR to survivin on cancer cells presented in MHC Class A3)
  • ABBV184  effective in vivo in lung cancer models as single agent;
  • in humanized mouse tumor models CD3/survivin bispecific can recruit T cells into solid tumors; multiple immune cells CD4 and CD8 positive T cells were found to infiltrate into tumor
  • therapeutic window as measured by cytokine release assays in tumor vs. normal cells very wide (>25 fold)
  • ABBV184 does not bind platelets and has good in vivo safety profile
  • First- in human dose determination trial: used in vitro cancer cell assays to determine 1st human dose
  • looking at AML and lung cancer indications
  • phase 1 trial is underway for safety and efficacy and determine phase 2 dose
  • survivin has very few mutations so they are not worried about a changing epitope of their target TCR peptide of choice

The discovery of TNO155: A first in class SHP2 inhibitor

Matthew J. LaMarche
Novartis @Novartis

  • SHP2 is an intracellular phosphatase that is upstream of MEK ERK pathway; has an SH2 domain and PTP domain
  • knockdown of SHP2 inhibits tumor growth and colony formation in soft agar
  • 55 TKIs there are very little phosphatase inhibitors; difficult to target the active catalytic site; inhibitors can be oxidized at the active site; so they tried to target the two domains and developed an allosteric inhibitor at binding site where three domains come together and stabilize it
  • they produced a number of chemical scaffolds that would bind and stabilize this allosteric site
  • block the redox reaction by blocking the cysteine in the binding site
  • lead compound had phototoxicity; used SAR analysis to improve affinity and reduce phototox effects
  • was very difficult to balance efficacy, binding properties, and tox by adjusting stuctures
  • TNO155 is their lead into trials
  • SHP2 expressed in T cells and they find good combo with I/O with uptick of CD8 cells
  • TNO155 is very selective no SHP1 inhibition; SHP2 can autoinhibit itself when three domains come together and stabilize; no cross reactivity with other phosphatases
  • they screened 1.5 million compounds and got low hit rate so that is why they needed to chemically engineer and improve on the classes they found as near hits

Closing Remarks


Xiaojing Wang
Genentech, Inc. @genentech

Follow on Twitter at:








Read Full Post »




Quantity Business Model Asset Protection

Transaction Type


Asset Class I




The Journal 3/3/2020 Views 1,723,051

5,742 articles on 3/3/2020



Valuation [$40M] done by Joel on Alex WP Data


Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia




Copyright Law




B2B & B2B & B2C



Asset Class II

BioMed e-Series https://pharmaceuticalint elligence.com/2019- vista/global-market- penetration-forecast-for- each-volume-in-the-16- volume-biomed-e- series/  


16 volumes


Valuation [$5M] done by Joel & Aviva



Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia




Copyright Law




B2B & B2B & B2C




Asset Class III


eProceedings https://pharmaceuticalint elligence.com/2019- vista/e-proceedings-and- tweet-collections-per- conference-2013-2020- viewsdownloads-x-100- real-time-coverage-of- 60-events-by-ala-sjw/


60 events Valuation [$1.4M]

done by Dr. Williams &





Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia





Copyright Law





B2B & B2B & B2C



Asset Class IV



Platform, composition of methods and workflows for the content creation of scientific curations





Customized Platform Infrastructure, Building Tools for new products, venturing to new Disciplines beyond HealthCare,knowhow contracts in new geographies  


Copyright Law and Proprietary Knowhow




internal and contracts



Type Quantity Business Model Asset Protection

Transaction Type


Asset Class V



Gallery of Biological Images in use in Articles and Books







Artifacts in the of Content Creation of PRIOR ART

Copyright upon EMBEDDED

in original curations

Internal Use – subsets per BioMed e- Series in Medical Specialties


Asset Class VI




Team of Experts



BIOs Final Improvement Team (FIT)




Factor of Content Creation

Personal Agreement s to become Employment     Contracts Post-Exit  





Asset Class VII



Royalties on BioMed e- Series:Page downloads, Book borrowings and Book sale



111,645 page downloads in total on 3/9/2020




Current Account Receivables



Royalties Agreement with KDP


Derivative of Interest in Content (120,000

Pages download in 16 books


Asset Class VIII



Subscribers to the Website



2,554 on 3/29/2020



Potential Account Receivables





Drivers of Loyalty & Success


Asset Class IX



& Intrinsic Value = Good Will






Potential Account Receivables



Copyright Law





Asset Class X  


Audio Library




Potential Account Receivables


Copyright Law


B2B & B2B & B2C



Type Quantity Business Model Asset Protection Transaction Type


Asset Classes

Unique Value Proposition Key Paying Customers Key Stakeholders

Unique Selling Point




Asset Class I


We create a new level of knowledge that is current and lively on the current issues and based on a discussion of multiple KOL


Legal, regulatory, Pharma R&D, Non academia, Gov, Journalists, media, Premium audience



academics, students, science addicts



Current high level accessible knowledge




Asset Class II


in depth as of day of publication knowledge collection of topic, background, good as a course or a journal club guide. State of the art, science based, outcome oriented KOL based perspective.


Legal, regulatory, pharma R&D, non academia, Gov, journalists and media, premium audience


Universities, Patient advocacy groups, Professional associations, Curriculum developers


current highly multiple domain specialized accessible knowledge





Asset Class III



In depth on publication day, knowledge collection of topic, depicts event spirit and highlights with KOL perspective and annotation, scientific documents and historical state of Science



Global Biotech & Healthcare Conference Organizers + Customers of Asset Class I+II



Conference Participants, Future Attendees & Participants Missing Conference Sessions




Real time, On demand, Event Tweet Collections




Asset Class IV

platform that allow harnessing the state of knowledge to produce a state of the art coverage of eventual or topic based current knowledge products to a specific targeted audience  

New topics, new geographies knowledge community makers, LPBI new products pipeline


the global KOL community in health, life- sciences and pharma



unique, easy, proven, state of the art

Transaction Type Unique Value Proposition Key Paying Customers Key Stakeholders Unique Selling Point
Asset Class V  


Selection done by Domain Experts for IP creation of original content






e-Readers, Publishers, Future Publishing Academics




Asset Class VI



Group of outcome-oriented KOLs in Health Care & Pharma Industry & Academia expertise




Human Capital asset

Asset Class VII  



Global reach




e-Readers of Science e-Books



Scientist- contributors on FIT and Past contributors

Asset Class VIII  

A reach into the top of the line Executives and KOLs in Pharma and Life sciences R&D


To be segmented and Targeted for Outreach and Outbound Marketing



Venture Owner

Top of the line, majority of the Global market leaders in Biotech


Asset Class IX



Product/Service Quality & Reputation



Acquirer and Its Customers


Asset Class X


Selection of most prominent Figures to be featured


Media Licensing Agreements




Transaction Type Unique Value Proposition Key Paying Customers Key Stakeholders Unique Selling Point

Read Full Post »

Is It Time for the Virtual Scientific Conference?: Coronavirus, Travel Restrictions, Conferences Cancelled

Curator: Stephen J. Williams, PhD.

UPDATED 3/12/2020

To many of us scientists, presenting and attending scientific meetings, especially international scientific conferences, are a crucial tool for disseminating and learning new trends and cutting edge findings occurring in our respective fields.  Large international meetings, like cancer focused meetings like AACR (held in the spring time), AAAS and ASCO not only highlight the past years great discoveries but are usually the first place where breakthroughs are made known to the scientific/medical community as well as the public.  In addition these conferences allow for scientists to learn some of the newest technologies crucial for their work in vendor exhibitions.

During the coronavirus pandemic, multiple cancellations of business travel, conferences, and even university based study abroad programs are being cancelled and these cancellations are now hitting the 2020 Spring and potentially summer scientific/medical conferences.  Indeed one such conference hosted by Amgen in Massachusetts was determined as an event where some attendees tested positive for the virus, and as such, now other attendees are being asked to self quarantine.

Today I received two emails on conference cancellations, one from Experimental Biology in California and another from The Cancer Letter, highlighting other conferences, including National Cancer Coalition Network (NCCN) meetings which had been canceled.


Experimental Biology - San Diego 2020 - April 4-7

Dear Stephen,

After thoughtful deliberations, the leaders of the Experimental Biology host societies have made the difficult but necessary decision to cancel Experimental Biology (EB) 2020 set to take place April 4–7 in San Diego, California. We know how much EB means to everyone, and we did not make this decision in haste. The health and safety of our members, attendees, their students, our staff, partners and our communities are our top priority.

As we have previously communicated via email, on experimentalbiology.org and elsewhere, EB leadership has been closely monitoring the spread of COVID-19 (coronavirus disease). Based on the latest guidance from public health officials, the travel bans implemented by different institutions and the state of emergency declared in California less than 48 hours ago, it became clear to us that canceling was the right course of action.

We thank you and the entire EB community for understanding the extreme difficulty of this decision and for your commitment to the success of this conference – from the thousands of attendees to the presenters, exhibitors and sponsors who shared their time, expertise, collaboration and leadership. We deeply appreciate your contributions to this community.

What Happens Next?

Everyone who has registered to attend the meeting will receive a full registration refund within the next 45 days. Once your registration cancellation is processed, you will receive confirmation in a separate email. You do not need to contact anyone at EB or your host society to initiate the process. Despite the cancellation of the meeting, we are pleased to tell you that we will publish abstracts in the April 2020 issue of The FASEB Journal as originally planned. Please remember to cancel any personal arrangements you’ve made, such as travel and housing reservations. 

We ask for patience as we evaluate our next steps, and we will alert you as additional information becomes available please see our FAQs for details.

And in The Cancer Letter

Coronavirus vs. oncology: Meeting cancellations, travel restrictions, fears about drug supply chain

By Alexandria Carolan

NOTE: An earlier version of this story was published March 4 on the web and was updated March 6 to include information about restricted travel for employees of cancer centers, meeting cancellations, potential disruptions to the drug supply chain, and funds allocated by U.S. Congress for combating the coronavirus.

Further updates will be posted as the story develops.

Forecasts of the inevitable spread of coronavirus can be difficult to ignore, especially at a time when many of us are making travel plans for this spring’s big cancer meetings.

The decision was made all the more difficult earlier this week, as cancer centers and at least one biotechnology company—Amgen—implemented travel bans that are expected to last through the end of March and beyond. The Cancer Letter was able to confirm such travel bans at Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center, and Dana-Farber Cancer Institute.

Meetings are getting cancelled in all fields, including oncology:

The National Comprehensive Cancer Network March 5 postponed its 2020 annual conference of about 1,500 attendees March 19-22 in Orlando, citing precautions against coronavirus.

“The health and safety of our attendees and the patients they take care of is our number one concern,” said Robert W. Carlson, chief executive officer of NCCN. “This was an incredibly difficult and disappointing decision to have to make. However, our conference attendees work to save the lives of immunocompromised people every day. Some of them are cancer survivors themselves, particularly at our patient advocacy pavilion. It’s our responsibility, in an abundance of caution, to safeguard them from any potential exposure to COVID-19.”

UPDATED 3/12/2020

And today the AACR canceled its yearly 2020 Meeting (https://www.aacr.org/meeting/aacr-annual-meeting-2020/coronavirus-information/)

The American Association for Cancer Research (AACR) Board of Directors has made the difficult decision, after careful consideration and comprehensive evaluation of currently available information related to the novel coronavirus (COVID-19) outbreak, to terminate the AACR Annual Meeting 2020, originally scheduled for April 24-29 in San Diego, California. A rescheduled meeting is being planned for later this year.

The AACR has been closely monitoring the rapidly increasing domestic and worldwide developments during the last several weeks related to COVID-19. This evidence-based decision was made after a thorough review and discussion of all factors impacting the Annual Meeting, including the U.S. government’s enforcement of restrictions on international travelers to enter the U.S.; the imposition of travel restrictions issued by U.S. government agencies, cancer centers, academic institutions, and pharmaceutical and biotech companies; and the counsel of infectious disease experts. It is clear that all of these elements significantly affect the ability of delegates, speakers, presenters of proffered papers, and exhibitors to participate fully in the Annual Meeting.

The health, safety, and security of all Annual Meeting attendees and the patients and communities they serve are the AACR’s highest priorities. While we believe that the decision to postpone the meeting is absolutely the correct one to safeguard our meeting participants from further potential exposure to the coronavirus, we also understand that this is a disappointing one for our stakeholders. There had been a great deal of excitement about the meeting, which was expected to be the largest ever AACR Annual Meeting, with more than 7,400 proffered papers, a projected total of 24,000 delegates from 80 countries and more than 500 exhibitors. We recognize that the presentation of new data, exchange of information, and opportunities for collaboration offered by the AACR Annual Meeting are highly valued by the entire cancer research community, and we are investigating options for rescheduling the Annual Meeting in the near future.

We thank all of our stakeholders for their patience and support at this time. Additional information regarding hotel reservation cancellations, registration refunds, and meeting logistics is available on the FAQ page on the AACR website. We will announce the dates and location of the rescheduled AACR Annual Meeting 2020 as soon as they are confirmed. Our heartfelt sympathies go out to everyone impacted by this global health crisis.

However,  according to both Dr. Fauci and Dr. Scott Gottlieb (former FDA director)  the outbreak may revisit the US and the world in the fall (see https://www.cnbc.com/2020/03/04/were-losing-valuable-time-ex-fda-chief-says-of-coronavirus-spread.html)  therefore these meetings may be cancelled for the whole year.

Is It Time For the Virtual (Real-Time) Conference?

Readers of this Online Access Journal are familiar with our ongoing commitment to open science and believe that forming networks of scientific experts in various fields using a social strategy is pertinent to enhancing the speed, reproducibility and novelty of important future scientific/medical discoveries.  Some of these ideas are highlighted in the following articles found on this site:

Scientific Curation Fostering Expert Networks and Open Innovation: Lessons from Clive Thompson and others

Old Industrial Revolution Paradigm of Education Needs to End: How Scientific Curation Can Transform Education

Twitter is Becoming a Powerful Tool in Science and Medicine

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

Reconstructed Science Communication for Open Access Online Scientific Curation

In addition, we understand the importance of communicating the latest scientific/medical discoveries in an open and rapid format, accessible over the social media platforms.  To this effect we have developed a methodology for real time conference coverage

see  Press and Conference Coverage

at  https://pharmaceuticalintelligence.com/press-coverage/


The Process of Real Time Coverage using Social Media

at https://pharmaceuticalintelligence.com/press-coverage/part-one-the-process-of-real-time-coverage-using-social-media/

Using these strategies we are able to communicate, in real time, analysis of conference coverage for a multitude of conferences.

Has technology and social media platforms now have enabled our ability to rapidly communicate, in a more open access platform, seminal discoveries and are scientists today amenable to virtual type of meetings including displaying abstracts using a real-time online platform?

Some of the Twitter analytics we have curated from such meetings show that conference attendees are rapidly adopting such social platforms to communicate with their peers and colleagues meeting notes.

Statistical Analysis of Tweet Feeds from the 14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment 9/30 – 10/1/2014 • Congress Center Basel – SACHS Associates, London

Word Associations of Twitter Discussions for 10th Annual Personalized Medicine Conference at the Harvard Medical School, November 12-13, 2014

Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950

Twitter Analytics on the Inside 3DPrinting Conference #I3DPConf


Other Twitter analyses of Conferences Covered by LPBI in Real Time have produced a similar conclusion: That conference attendees are very engaged over social media networks to discuss, share, and gain new insights into material presented at these conferences, especially international conferences.

And although attracting international conferences is lucrative to many cities, the loss in revenue to organizations, as well as the loss of intellectual capital is indeed equally as great.  

Maybe there is room for such type of conferences in the future, and attending by a vast more audience than currently capable. And perhaps the #openscience movement like @MozillaScience can collaborate with hackathons to produce the platforms for such an online movement of scientific conferences as a Plan B.

Other articles on Real Time Conference Coverage in the Online Open Access Journal Include:

Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Tweets by @pharma_BI and by @AVIVA1950: Real Time Coverage and eProceedings of The 11th Annual Personalized Medicine Conference, November 18-19, 2015, Harvard Medical School

REAL TIME Cancer Conference Coverage: A Novel Methodology for Authentic Reporting on Presentations and Discussions launched via Twitter.com @ The 2nd ANNUAL Sachs Cancer Bio Partnering & Investment Forum in Drug Development, 19th March 2014 • New York Academy of Sciences • USA

Search Results for ‘Real Time Conference’

Read Full Post »

Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

Author: Aviva Lev-Ari, PhD, RN


How to Value a Website or Internet Business in 2020


From: Thomas Smale <acquisitions@feinternational.com>

Reply-To: <acquisitions@feinternational.com>

Date: Thursday, February 27, 2020 at 4:30 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Your Guide to Buying an Online Business

Hi Aviva

Thanks for your interest in our free Guide to Buying an Online Business. Please click below to download.



We will be in touch in a few days to see if you have any questions!


Thomas Smale

FE International, Inc.


Follow us on FacebookLinkedIn and Twitter.


FE International Framework

Alternative Metrics for Valuing Websites Or Internet Business

  • Discounted Cashflow Analysis
  • Precedent Transactions
  • Earnings-Multiple
  • Traffic Valuation
  • A Multiple-Based Approach to Valuing a Website or Internet Business

Defining Profitability

Factors That Influence The Multiple: Financials, Traffic, Operations, niche, Customer base

Valuation Multiples In Practice

Image source:


Consider the Current Business Model

How to Value a SaaS Business

How to Value an E-Commerce Business

How to Value an App


Reservations on Applicability of Financial & Economic Valuation Models for Internet Businesses or Websites by FE International for CONTENT Creation ventures where Intellectual Property (IP) and Intangibles Assets (ITA) are the Business Value Drivers

On 2/27/2020 5:30AM – Aviva Wrote:

This is an excellent article.

It is very applicable for

1. Travel Websites

2. eCommerce transaction sites

3. Content: chiefly NEWS


Our PharmaceuticalIntellugence.com

A. Is an Internet based Business of Digital Content

B. Unlike 1,2,3 – 

B.1 EVERY CURATION in the Journal

has content with INTRINSIC value in the form of IP belonging to the Curator’s Expertise

B.2 ALL 16 Volumes in the BioMed e-Series represent an ORIGINAL electronic Table of Contents eTOCs designed by a very unique Editor(s).

B.2.1 The evolution of the eTOCs takes many iterations among the editors AND only the Editor-in-Chief after requests for substantial alterations, usually ADD new content, declares “This is the final eTOCs for Series X, Volume Y.

(These alterations AUGMENT the IP embedded in the eTOCs design)


Genomics Volume 2: there were three iterations of eTOCs between Prof. Feldman and Aviva, first dated 2016. 

In 2019, 

• Aviva created single handedly the FINAL version of eTOCs and 

• commissioned ALL scientists to populated Parts 7 and 8 with new content not in existence in the Journal. 

• made Part 3: AI in Medicine

• made Part 4: Single Cell Sequencing

• obtained from Part 5: Evolution & Genomics from Prof. Feldman as an original curations WRITTEN for this Volume 

THAT IS INTRINSIC VALUE DERIVED FROM EXPERTISE and it defines the QUALITY of this book, which is not measured by traffic. Advertisement of the book could drive page downloads and book sales. It can be done ANY TIME because each article in the book is updated in perpetuity !! A feature of our BioMed e-Series.

Does the DCF model capture the value of NON-perishable content in our Jornal and Books – no it does not

It will be valued at PREMIUM an acquirer who is sensitive to content obsolescence !!!!!

B.2.2 Page downloading will be updated for 4/19/2020

C. eProceedings are generated by Experts and the TWEET Collections carry the favorable Tweet Analytics that we presented: 

• HIGH engagement, 

• HIGHEST ratio tweet/likes in the Industry

• Ranked 2nd, 3rd, 4th in TOP 10 Influencers at #1 Conference in AI in Medicine in the World, 4/2019

HOW THUS VALUATION article calling for 2 to 4.5 multiplier is to capture LPBI’s

1. ECONOMIC intrinsic value on non perishable content 

2. Top Expertise

3. electronic Reputation and other INTANGIBLE ASSETS as VALUE DRIVERS

FE International’s model has only LIMITED applicability to valuation of LPBI Portfolio of Intellectual Property.

Our venture shares several industries, we have identified 12 economic segments where an acquirer can be identified. The content created using the methodology of curation of scientific findings with clinical interpretation by experts was developed in house to mitigate the information explosion in the Life Sciences and the information obsolescence. The content lands its attribution to electronic Scientific Publishing and to Pharmaceutical Media. Please review the business functions that this content could contribute to by the value drivers in each economic segment https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

Introduction to Three Intellectual Property Asset Classes of Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston


  •  LPBI Scientific Journal: 1.7Million eReaders, 5700 scientific articles [Pharmaceutics, Life Sciences, Medicine], 690 categories of research, 10,154Tags


  • BioMed e-Series: 16 Volumes in Medicine and Life Sciences


  •  e-Proceedings: Corpus of +70 Biotech & Medical Conferences, events covered in real time by a methodology developed in house yielding the e-Proceeding with one click at the end of the Conference.



  • Asset Class IV is the platform, composition of methods and workflows for the content creation of scientific curations
  • Asset Class V is a Gallery of ~5000 images used in the articles and books
  • Asset Class VI is the Team of Experts.
  • Asset Class VII: Royalties on BioMed e-Series

Read Full Post »

Older Posts »